

Chapter 1: Bridging Gaps in PCOS Care: The Nanotechnology Revolution Begins

Jhilli Basu¹, Jyoti Devi¹, Diksha Chauhan¹, Priya Jaswal¹, Binita Ghosh²

¹Maharishi Markandeshwar Medical College and Hospital, Maharishi Markandeshwar University, Sultanpur-Kumarhatti-173229, Solan, Himachal Pradesh, India.

²Mahatama Gandhi College of Pharmaceutical Sciences, Tonk Road, Jaipur, Rajasthan, India.

Correspondence Author*

Priya Jaswal

Email: priya21jaswal@gmail.com

Abstract

Polycystic ovary syndrome (PCOS) is a rather complex endocrine and metabolic disorder with multiple factors involved, and it is a disorder that affects the lives of millions of women worldwide. Among its symptoms are hormone imbalance, high blood sugar levels, lack of ovulation, and inflammation. These together lead to the syndrome being the main reason for women's infertility caused by anovulation. Even though there are remarkable improvements in diagnostics and drug therapies, the traditional medical strategies for PCOS treatment are often hindered by limitations such as non-specificity, poor bioavailability, high chances of adverse effects and diminishing long-term efficacy. Hence the call for more precise and effective treatment methods is louder than ever. Nanotechnology is a novel approach to this crying need that can give breakthroughs through advanced drug delivery systems at the molecular level. The researchers have come up with various nanotechnology-based formulations-polymeric nanoparticles, solid-lipid nanoparticles, and nanoemulsions-that provide many advantages, including better bioavailability, longer systemic half-life, and lesser inflammatory responses. The anti-diabetics, hormone modulators, insulin sensitizers, and anti-inflammatory phytochemicals have been among the categories of drugs that have been delivered via these nanoformulations. Nanomedicine has not only made the delivery of the drugs more precise but has also opened up the area of gene therapy and ovarian-targeted delivery. This makes personalized and regenerative treatments in reproductive endocrinology possible. The conjugation of targeted ligands further escalates the accuracy of drug delivery, thus magnifying therapeutic efficacy and minimizing adverse effects at the same time. This chapter deals with the pathophysiology of PCOS, elaborates the therapeutic role of nanomedicine in its management and gives an overview of the newest developments in nanotechnology-based treatment strategies.

Keywords: *Nanotechnology, Hyperandrogenism, Ovulatory dysfunction, Ligands, Gene-specific nanomedicine.*

1. INTRODUCTION

Irritable Bowel Syndrome (IBS) is a gut disorder characterized by an abnormally increased response toward those various stimulants that are only mild. The PCOS disrupts the normal functionality of the ovaries; thus, has a unique clinical profile that includes menstrual irregularity (oligomenorrhea or amenorrhea), biochemical or clinical hyperandrogenism, and polycystic morphology of the ovary (Ghafari et al., 2025). These all conditions are the consequences of hormonal and metabolic imbalances leading to symptoms ranging up to abnormal menstrual periods to infertility, acne, hirsutism, and androgenic balding (Dewani et al., 2023) (**Fig. 1.1**).



<u>Healthy</u>	<u>Features of women's ovary</u>	<u>PCOS</u>
Fewer developing follicles	Ovarian Structure	Many immature follicles (cysts)
Balanced estrogen & progesterone	Hormonal Profile	Elevated androgens (testosterone)
Regular	Menstrual Cycle	Irregular or absent
Regular; Fertile	Ovulation	Irregular or absent; Infertility
Follicles mature and release egg	Follicle Maturity	Follicles fail to mature
None	Associated Symptoms	Hirsutism, acne, weight gain, insulin resistance

Figure 1.1: Representation of ovarian morphology

The pathogenesis of PCOS is multifactorial; which means it has genetic factors, environmental factors, and extreme metabolic disorders. Insulin resistance is one of the pathophysiological processes ubiquitous among the affected individuals (Purwar & Nagpure, 2022). The development of hyperinsulinemia via compromised insulin signaling facilitates androgen excess production by theca cells, causes an ovarian stroma hyperplasia, and worsens hyperandrogenism and anovulation (Unluhizarci et al., 2021). Commonly present along with insulin resistance is obesity; which further deteriorate the condition, and causes impairment of endocrine homeostasis, making obesity another notable associated factor in severity of symptoms (Ezeh et al., 2024). Critical manifestations also lack homogeneity and may even comprise reproductive,

skin, and metabolic alterations. Amenorrhea and poor fertility are the most frequent links to anovulation, high levels in androgens cause cutaneous disorders, hirsutism, and acne. Conventionally, a diagnosis is made by applying the rotterdam criteria that require the two out of the three conditions: anovulation, clinical/biochemical hyperandrogenism, ultrasonographic polycystic ovary appearance (Christ & Cedars, 2023). Transvaginal ultrasonography (TVS) provides the common findings of enlarged ovaries with increased stromal volume and peripheral numerous follicles which is classically referred to as a string of pearls (Bae et al., 2023). This morphology however, is not diagnostic and pathognomonic in itself and has to be interpreted regarding the wider clinical scenario. Biochemically, it is often shown that there is an increase in the serum total and free testosterone concentrations, an imbalanced luteinizing hormone/follicle stimulating hormone (LH/FSH) proportion (Merza et al., 2025). Beyond reproductive implications, PCOS is also associated with numerous long-term health risks like metabolic syndrome (which is a combination of central obesity and hypertension), dyslipidemia, disrupted glucose insulin, increases cardiovascular disease and type 2 diabetes mellitus (T2DM) (Livadas et al., 2022). Anovulation in consistent cases leads to a chronic exposure to estrogens unopposed by progesterone, and thus increases the chances of developing endometrial hyperplasia and subsequent development of endometrial carcinoma (Montanino Oliva et al., 2022).

Even though currently no cure is proposed, there is a possibility to employ a range of symptom-based interventions. These are modifications in lifestyle, insulin-sensitizing pharmacotherapy, hormonal contraceptives, anti-androgens, and ovulation induction pharmacotherapy (Rashid et al., 2022). The screening of prevalence and individualized approach to a treatment are important to avoid complications and enhance the quality of life. Targeted drug delivery and finely adjusted hormonal regulation are the prospects of innovative nanotechnology-based methods and can multiply the therapeutic effect while reducing the side effects affecting the women's body (Sahu et al., 2021).

2. PATHOPHYSIOLOGY OF POLYCYSTIC OVARY SYNDROME

PCOS is a multifactorial condition in which the development of the disease is accompanied by a high degree of hormonal and metabolic disturbances, which is the basis of its pathology (**Fig.1.2**). A detailed knowledge of these disruptions is very essential in the exact diagnosis as well as to the successful treatment of the condition.




Figure. 1.2: Hormonal and Metabolic Fluctuations in PCOS

2.1 Hormonal Imbalances in PCOS

In clinical practice, the most notable pathophysiological aspect of PCOS is the reproductive imbalance of hormones, most prominently an elevation of androgens often referred to as male hormones (Su et al., 2025). Male sex hormones are also present in female (because of androgens secreted by the adrenal glands in both genders and ovaries in females); but in much smaller concentrations. However, in PCOS patients androgens are overproduced by the ovaries; thus triggering a number of clinical symptoms like reduced ovulation that frequently leads to abnormal or stopping of menstruation, hirsutism (excessive hair growth on the upper lip, chin, chest, and abdomen), acne and hyperseborrhea (oily skins) (K. Wang et al., 2023). The thinning of the hair on the head or the female pattern baldness whereby one notices the loss of hair density on the head. All these symptoms are the result of the hormonal imbalance that is created by PCOS, and can significantly affect the physical appearance and the self-esteem of the women. Other reproductive hormones are also abnormal in PCOS, which is coupled with elevated levels of androgens in the serum. Specifically, a high LH/FSH ratio is also of interest since it further disrupts normal ovulation and thus leads to irregular or missed periods (Merza et al., 2025). A significant change in the level of estrogen might not occur in most women who are diagnosed with PCOS but the overall effects of elevated testosterone, reduced or complete lack of progesterone production; can lead to the impairment of ordinary reproductive control which makes the fertility problem even more severe.

2.2 Metabolic Dysregulation in PCOS

The metabolic issues in the condition of PCOS closely associated with the insulin resistance. Insulin is known to act as the primary controller of the plasma glucose

levels and adipose stores; but maximally in women with PCOS the insulin sensitivity of peripheral tissues is disrupted, which further leads to hyperinsulinemia (Purwar & Nagpure, 2022; Unluhizarci et al., 2021). The increased insulin levels further stimulate increased androgen synthesis of the adrenal glands and thereby increasing hormonal imbalances. Insulin resistance is predisposing the women with PCOS to gain weight, which is closely linked to increased adiposity in the abdomen (Barber & Franks, 2021). Besides, excessive central adiposity that is positioned within the spinal column is a very well-known factor with regard to the excessive weight gain, and the pronounced phenotypes commonly expressed in a majority of the patients with PCOS (Gorgey et al., 2021). The body's glucose tolerance can also be impaired with the progressive insulin resistance, which significantly increases the occurrence of the onset of T2DM (Livadas et al., 2022). At the same time, metabolic abnormalities like insulin resistance, hypercholesterolemia and hypertension also increase long-term cardiovascular risk profiles.

3. EXISTING INTERVENTIONS-WHAT WE ACTUALLY HAVE!

The modern paradigm of PCOS treatment is based on the combination of integrative and pharmacological treatment in the form of lifestyle adjustment based on healthy nutrition and moderate physical activity with medications; aimed at correcting the clinical symptoms and normalizing hormone levels (Mohammed et al., 2024). Individual treatment plan based upon the diagnostics/clinical findings which my menstruation irregularities, infertility and the metabolic issues. Common pharmacological treatments used in PCOS are hormonal contraceptives, androgen blocking and insulin sensitizing drugs with the most commonly used being metformin (Rashid et al., 2022). Although every medication has their own specific associated risks (**Fig. 1.1**); these shortcomings demonstrate the necessity of optimizing current strategies and creating new interventions that reduce the incidence of adverse effects and increase the effectiveness of the treatment (Maan et al., 2025; H. Zhao et al., 2023).

Table 1.1: Medication for Symptomatic Relief in PCOS with their Associated Risks

Pharmacological Class	Medication	Side Effects
Combined Oral Contraceptives (COS's)	Estrogen and Progestin	Nausea, breast tenderness, and breakthrough bleeding. Contraindication: Patient with history of blood clots and liver disease (Oguz & Yildiz, 2021).
Anti-Androgen Medications	Spironolactone or Cyproterone acetate	Dizziness, fatigue, and irregular menstrual bleeding. Contraindication: pregnancy due to the risk of feminization of male fetuses (Sabbadin et al., 2016).

Gonadotropin-releasing hormone (GnRH) Agonists	Leuprolide or Goserelin	Hot flashes, vaginal dryness, and mood swings. Contraindication: long-term use can create the risk of loss of bone integrity (Heery, Aprn, Aocns, Cbcn et al., 2020).
Fertility Medications	Clomiphene citrate	Hot flashes, mood swings, and ovarian hyperstimulation syndrome (Yilmaz et al., 2018).
Insulin Sensitizers	Pioglitazone, some time in combination with metformin	Weight gain, fluid retention, and an increased risk of heart failure. Contraindication: Regular monitoring of liver enzymes is recommended due to the potential for liver toxicity (Sheikh et al., 2023).
Inositols	Myo-Inositol, D-Chiro-Inositol	Generally well-tolerated, but some individuals may experience gastrointestinal symptoms like nausea or diarrhea.
Glucocorticoids	Dexamethasone	Long-term use of glucocorticoids may be associated with adrenal suppression, weight gain, and increased susceptibility to infections (Yoon et al., 2021).
Aromatase inhibitors	Letrozole or Anastrozole	Hot flashes, headaches, and joint pain.

4. NANOFORMULATIONS-AN EMERGING THERAPEUTICS FOR ENDOCRINE METABOLIC DISORDERS

The anatomically configured drug delivery vehicles (categorized as nano carriers; the average size generally lies between 1-100 nm); that are able to deliver therapeutic agent to a specific destination (cell/tissue) in the body resulting to a reduction of the overall toxicity of the product as well as an improved bioavailability (Altammar, 2023). The key nanocarriers would include liposomes, nanoparticle, polymer micelles, dendrimers, nanospheres, nano-capsules, silica nanoparticles, inorganic nanoparticles, carbon nanotubes, exosomes, micro-vesicles, and hydrogel nanocarriers (Prathamesh R. Sune et al., 2024). There are ways to treat PCOS pharmacologically, but the future of nanotechnology can help to treat the syndrome more effectively, specific to each patient, and a step closer to personalized health care; thus, may help to improve the quality of women’s life. Research and development in nanotechnology in PCOS care are valuable as there are a number of reasons that have made this technology interesting.

4.1 Site Specific Therapy: Nanotechnology has led to development of targeted use of the drug delivery system, which has the potential of increasing efficacy of therapeutic intervention with negligible side effects (Sahu et al., 2021). Traditionally, the standard therapy of PCOS is taking the systematic medications, which cause undesired effects because of non-specificity. As an example, metformin (which is a

major drug that treats insulin resistance in PCOS) may have gastrointestinal side effects, many of which appear in patients. In this system, drug moiety may be embedded into nanoparticles and then be released at a desired point such as ovaries or insulin sensitive tissues. This does not only maximize the therapeutic effects, but also reduce the unwanted side effects that come with higher doses taken by the women's (Basu et al., 2024). Moreover, it is possible to introduce specialized ligands on these delivery vehicles to increase the tissue specificity, making them more efficacious and personalized to the needs of their patients. These breakthroughs in localized drug therapy may lead to the development of more effective and safer PCOS management approaches to the persons affected by this condition.

Antioxidant and Anti-inflammatory Nanocarriers: There is a multiplicity of indications showing that the oxidative stress and chronic inflammation are two key pathological determinants of PCOS. There is a chance to improve the management of antioxidants and anti-inflammatory substances using nanomaterial-based technologies against these processes. This includes liposomes, dendrimers, and polymeric nanoparticles have the potential to entrap the therapeutic moiety; which enhances stability, solubility, and bioavailability of the molecule (Basu et al., 2024). These nanocarriers based systems are also suitable to the antioxidant agents like curcumin or resveratrol that have already proved their potential to reduce the oxidative stress in females with PCOS (Rodríguez-Yoldi, 2021). Precise administration of such nanocarriers helps to not only alleviate inflammatory responses but also positively influence the metabolic condition of patients.

4.2 Biosensors-Based Detection System: The application of nanomaterials presents a potential opportunity in the development of extremely sensitive biosensors that have the capability to detect PCOS at a point before its serious manifestations (Malik et al., 2023). This type of device may determine the presence of certain biomarkers including an increased testosterone or insulin level through a routine blood sample, thus enabling a diagnosis and action at an earlier stages (Lino et al., 2022). A non-invasive biosensor that can measure a variety of biomarkers in interstitial fluid or sweat would enable detecting hyperandrogenism early and take action at the right time. Blood-sugar spikes may also be recognized through continuous glucose monitoring (CGM); which will make it possible to implement lifestyle changes to minimize the impact of insulin resistance and reduce the likelihood of T2DM (Hanssen et al., 2020). Moreover, biosensors that involve the use of nanoparticles and measure the concentrations of the inflammatory factors, such as C-reactive protein would give us even more insight into chronic inflammation which is prevalent in the condition of PCOS. It is also possible that the ovarian morphology and follicular dystrophy may be tracked with the use of portable ultrasound devices combined with the artificial-

intelligence algorithm, which would contribute to earlier diagnosis and better control of the condition (H. Wang & Yang, 2025).

4.3 Novel Imaging Techniques: Nanoparticle application has achieved remarkable improvement in imaging applications that can be used to study ovarian functions and morphology; thus leading to the diagnosis, tracking and treatment of ovarian cysts in PCOS (S. Singh et al., 2024). The major procedure used to examine the ovary and to identify the development of cysts is TVS, yet a positive increase in spatial resolution can be achieved only to a certain extent by software implementation (X. Luo et al., 2024). New research has shown that bio-degradable nanoparticle additions to microbubble preparations, make it possible to significantly increase echogenicity that can be used to better distinguish functional cysts and other benign anatomic structures. Magnetic resonance imaging (MRI) provides better soft-tissue contrast to enable precise evaluation of ovarian tissues and the related complications such as endometrial thickening in PCOS patients. A further step to improve the quality of MRI images and to focus on the PCOS-related biomarkers in the diagnoses is the inclusion of superparamagnetic nanoparticles into the MRI contrast agents (D. Singh, 2025). In spite of the fact that computed tomography (CT) is not standardly necessary in the management of PCOS; it may provide useful data on abdominal and pelvic organ pathologies. This CT contrast medium, which is usually applied in the form of nanoparticle preparation, can be valued in the assessment of the ovarian tissues, especially in the difference between normality and pathology. Optical imaging procedures including fluorescence microscopy, can be used to utilise quantum-dot fluorescent labels to bind specifically to increased hormones and proteins in the body and hence can be used to detect non-invasively hormonal dysregulation in PCOS (Dixit & Mishra, 2025).

4.4 Genetics and Nanoplatforms: In the recent year's, genetic medicine or gene therapy is another therapeutic approach towards hormonal disturbances underlying PCOS (Gonzalez et al., 2025). With the help of nano systems, nucleic acid transfection to target cells is streamlined safely and genomic contents against degradation and encourage intracellular transport (Parashar et al., 2025). Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 is one of the gene based therapeutic interventions utilizing nanoparticle vehicles or carriers, which can inhibit or boost insulin resistance, androgen production, and ovary-associated genes (Balasubramanian et al., 2024). The applications have the potential to create more targeted and individualized management of women with PCOS and may reverse or alleviate associated symptoms.

4.5 Enhanced Bioavailability: Nanoparticles may allow a higher form of bioavailability as certain drugs have an increased rate of solubility and absorption (Liu et al., 2024). This plays a pivotal role in drugs that effectiveness is hindered by low gastrointestinal tract absorption. The phenomena of low aqueous solubility of Paclitaxel, one of the most well-known anticancer drugs, have induced the development of lipid-based nanoparticles. With the entrapment of Paclitaxel in these nanoparticles of lipid, scientists are able to increase its dissolvability, as well as its ability to be absorbed in the gastrointestinal tract in the case of oral intake, or they can help the ease of its distribution to tumor foci by intravenous transfer (S. Zhao et al., 2022). These nanoparticles are involved in the controlled release property so that the therapeutic efficacy is maintained. The empirical results of preclinical and clinical studies show that paclitaxel-loaded lipid nanoparticles produce a significant increase in bioavailability, therapeutic potential, and a simultaneous decrease in the side effects in comparison with the reference agents (S. Zhao et al., 2022).

4.6 Nanotherapeutics as a Personalized Approach: Nano strategies based personalized healthcare is an important step in PCOS care. The nanoscale provides a means of making interventions specific to the pathophysiological state of the individual, their genetic makeup, and their measure of response to treatment (Moka et al., 2025). A breakthrough example is the use of nanoparticles that are designed to overcome the effects of insulin resistance which is characteristic of PCOS. By making these particles functional to target insulin-sensitive tissues/ligands, they demonstrated targeted-delivery of metformin with an enhanced glucose metabolism throughout the body; with fewer or no adverse effects in the body (Purwar & Nagpure, 2022). Additionally, nano sensors may be manufactured to assess the changes in hormones and metabolic markers in real-time, and the personalized feedback on lifestyle interventions should be provided (Malik et al., 2023). Together, these advancements indicate that the integration of nanotechnology and personalized medicine holds potential to better maintain PCOS and, in the end, create a positive improvement in the quality of life of the affected women.

4.7 Reproductive Health Innovations: The latest discoveries in nanotechnology are a potential prospect in the development of interventional procedures to resolve reproductive problems that are related to PCOS (Veerasingh, 2024). Researchers are also developing nanoscale drug-delivery vehicles that can deliver site-specific drug interventions that specifically target the ovaries, such as a nanoparticle-based drug that can be used to direct the hormonal treatment of the ovaries in a controlled manner, this would be better at restoring normal ovarian functioning in comparison with conventional treatment methods (Prakash, 2023). Further, nanotechnology is being applied in refinement of fertility treatment through enhancement of oocyte quality, and

increase in commercial success rates of in vitro fertilization (IVF) (Guo et al., 2023). Similar attempts include the hydrogels with a functionality that behaves like ovarian follicles coupled to mechanical and chemical hints that can potentially enhance the viability and development ability of follicular cells (Cao et al., 2021). In total, these new approaches bring a positive perspective on the multimodal treatment of PCOS.

4.8 Addressing Co-morbidities and Improving Patient Compliance: PCOS is characterized by various co-morbidities most notably obesity and metabolic syndrome; where nanotechnology can be used as the key mechanism used to combat such complications and allows the care to be expanded beyond reproductive symptom treatment to extended metabolic and physiological support (Kim, 2021). Insulin-insensitivity and metabolic dysregulation that is typically the main core of PCOS are diminished by engineered nanoparticles made up of lipid-based systems with metformin to increase insulin sensitivity (Kaushal et al., 2025). Another example is the targeted nano delivery of the antioxidant compounds has been also a solution to reduce the inflammation linked to PCOS and hence manage weight as well as metabolic health (Mukherjee et al., 2024). Moreover, nanotechnology in a pharmaceutical formulation has the potential to enhance patient adherence due to longer-acting systems, decreasing doses, and making treatments easier and simpler to deal with; especially insulin resistance.

5. NANOTECHNOLOGY AND HERBS: A COMPLEMENTARY APPROACH

PCOS is a complicated hormonal disorder that has been treated in the past in terms of lifestyle modification and pharmacotherapy; but recently with the innovation in nanomedicines or herbal therapeutics fusion with nanosystems makes the treatment strategies of PCOS very advance (Fig.1.3).




Figure 1.3: An insight into Herbal-Nanosystems Fusion

Recent studies indicate that herbal medicines do have an appreciable impact on androgen physiology within the body, follicular growth and glucose homeostasis (Salm et al., 2023). Herbs like spearmint has anti-androgenic factors which have the potential of normalizing androgen and *Vitex agnus-castus* supports periodicity of the menstrual cycle (Grant, 2010; Höller et al., 2024). The insulin-enhancing properties of Cinnamon (*Cinnamomum zeylanicum*), hormone-balancing property of maca root (*Lepidium meyenii*), and adaptogenic properties of holy basil (*Ocimum tenuiflorum*) reduce existent metabolic complications and strengthen physiological well-being, respectively (Jamshidi & Cohen, 2017; Meissner et al., 2006; Shang et al., 2021). Some other phytochemicals like flavonoids, epigallocatechin-3-gallate (EGCG), polyphenols and omega-3 fatty acids in their nanoformulations have been found to have better metabolic and endocrine status too (Fukutomi et al., 2021; Intharuksa et al., 2024). Nanotechnology enhances the therapeutic effect of such occurring substances by making them more bioavailable, more stable, and administrable with specificity and control. These integrative modalities hold a great promise, but such a database should be validated clinically. Women who think of such therapies are recommended to seek consultation of medical experts in order to come up with safe and effective treatment planning. The combination of nanotechnology with herbal medicine therefore offers new avenues to enhancing the therapeutic value of plant derived substances in most therapeutic spectrums. However, challenges still exist, which include establishing toxicity and safety of nanoparticles, navigating through regulating processes (because nanoparticles have two properties), and maintaining standardization of herbal ingredients and bioactive compounds (R. Kumar, 2023; Teja et al., 2022). Research is also focuses on making such formulations easier, developing novel methods of delivery and strong safety measures so that the process of translation to clinical use in the future can be simplified (Gupta et al., 2025).

CONCLUSION

The combination of nanotechnology with herbal or pharmacological platforms has modified modern paradigms of reproductive and metabolic well-being. Treatment of PCOS by nanoscale materials has the potential to increase the drug bioavailability, prolong the drug half-life, and enable targeted delivery of drugs to overcome known therapeutic draw backs of PCOS. The innovations are not only expected to enhance pharmacokinetic profiles, but also to reduce adverse effects that are a crucial factor in the prolonged treatment of endocrine disorders. Nanocrystal-based formulations and nanoemulsions are future applications of nanomedical formulations that have demonstrated the possibility of better clinical outcomes. However, the domain is still new: mechanistic studies should be conducted using strict protocols and large-scale clinical trials should be done to clearly define efficacy, safety, and possibility of incorporating it into widespread use. Nanotechnology is likely to transform how the future is managed by providing a more personalized, effective and sustainable therapeutic strategy in dealing with PCOS.

Acknowledgement: Authors would like to thank Editors, Deep Science Publishers and Department of Pharmacy, Jagannath University to provide this opportunity.

Author Contribution: All authors have equal contributions in completion of this book chapter.

Funding: No funding.

Conflict of Interest: There is no conflict of interest.

REFERENCES

- A machine learning approach for non-invasive PCOS diagnosis from ultrasound and clinical features* | *Scientific Reports*. (n.d.). Retrieved October 9, 2025, from <https://www.nature.com/articles/s41598-025-10453-9>
- Abdallah, A. B. E., El-Ghannam, M. A., Hasan, A. A., Mohammad, L. G., Mesalam, N. M., & Alsayed, R. M. (2023). Selenium Nanoparticles Modulate Steroidogenesis-Related Genes and Improve Ovarian Functions via Regulating Androgen Receptors Expression in Polycystic Ovary Syndrome Rat Model. *Biological Trace Element Research*, *201*(12), 5721–5733. <https://doi.org/10.1007/s12011-023-03616-0>
- Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review—PMC*. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC9868606/>
- Ahmad, S., Jaiswal, R., Yadav, R., & Verma, S. (2024). Recent advances in green chemistry approaches for pharmaceutical synthesis. *Sustainable Chemistry One World*, *4*, 100029. <https://doi.org/10.1016/j.scowo.2024.100029>
- Ali, F., Neha, K., & Parveen, S. (2023). Current regulatory landscape of nanomaterials and nanomedicines: A global perspective. *Journal of Drug Delivery Science and Technology*, *80*, 104118. <https://doi.org/10.1016/j.jddst.2022.104118>
- Altammar, K. A. (2023). A review on nanoparticles: Characteristics, synthesis, applications, and challenges. *Frontiers in Microbiology*, *14*, 1155622. <https://doi.org/10.3389/fmicb.2023.1155622>
- Alwan, S. H., & Al-Saeed, M. H. (2023). Silver Nanoparticles Biofabricated from *Cinnamomum zeylanicum* Reduce IL-6, IL-18, and TNF- α in Female Rats with Polycystic Ovarian Syndrome. *International Journal of Fertility and Sterility*, *17*(1), 80–84. <https://doi.org/10.22074/IJFS.2022.539396.1189>
- Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review—PMC*. (n.d.). Retrieved September 27, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC11524647/>
- Bae, G., Berezhnoy, G., Koch, A., Cannet, C., Schäfer, H., Kommoss, S., Brucker, S., Beziere, N., & Trautwein, C. (2023). Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers. *Frontiers in Molecular Biosciences*, *10*, 1158330. <https://doi.org/10.3389/fmolb.2023.1158330>
- Balash, M., Boucetta, H., & He, W. (2025). Factors affecting drug delivery system translation: A focus on advanced technologies, biological barriers, and regulatory challenges. *Journal of Controlled Release*, *387*, 114167. <https://doi.org/10.1016/j.jconrel.2025.114167>
- Balasubramanian, A., Veluswami, K., Rao, S., Aggarwal, S., & Mani, S. (2024). Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review. *Cureus*. <https://doi.org/10.7759/cureus.64324>
- Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. *Clinical Endocrinology*, *95*(4), 531–541. <https://doi.org/10.1111/cen.14421>
- Basu, S., Biswas, P., Anto, M., Singh, N., & Mukherjee, K. (2024). Nanomaterial-enabled drug transport systems: A comprehensive exploration of current developments and future avenues in therapeutic delivery. *3 Biotech*, *14*(12), 289. <https://doi.org/10.1007/s13205-024-04135-y>
- Beca, J. M., Chan, K. K. W., Naimark, D. M. J., & Pechlivanoglou, P. (2021). Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: A simulation study. *BMC Medical Research Methodology*, *21*, 282. <https://doi.org/10.1186/s12874-021-01468-7>

Butt, M. A., Tabassum, S., Hardy, R. S., & Kiyani, M. M. (2025). Mechanistic insight into nanomedicine for polycystic ovary syndrome. *Molecular Biology Reports*, 52(1), 618. <https://doi.org/10.1007/s11033-025-10709-7>

Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. (n.d.). Retrieved October 9, 2025, from <https://www.mdpi.com/1420-3049/28/13/5145>

Cao, H., Duan, L., Zhang, Y., Cao, J., & Zhang, K. (2021). Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. *Signal Transduction and Targeted Therapy*, 6(1), 426. <https://doi.org/10.1038/s41392-021-00830-x>

Che, Y., Yu, J., Li, Y.-S., Zhu, Y.-C., & Tao, T. (2023). Polycystic Ovary Syndrome: Challenges and Possible Solutions. *Journal of Clinical Medicine*, 12(4), 1500. <https://doi.org/10.3390/jcm12041500>

Chen, W., & Pang, Y. (2021). Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. *Metabolites*, 11(12), 869. <https://doi.org/10.3390/metabo11120869>

Christ, J. P., & Cedars, M. I. (2023). Current Guidelines for Diagnosing PCOS. *Diagnostics*, 13(6), 1113. <https://doi.org/10.3390/diagnostics13061113>

Cinti, C., Trivella, M. G., Joulie, M., Ayoub, H., & Frenzel, M. (2024). The Roadmap toward Personalized Medicine: Challenges and Opportunities. *Journal of Personalized Medicine*, 14(6), 546. <https://doi.org/10.3390/jpm14060546>

CRISPR Technology Information | Thermo Fisher Scientific—IN. (n.d.). Retrieved October 9, 2025, from https://www.thermofisher.com/in/en/home/life-science/genome-editing/genome-editing-learning-center/crispr-cas9-technology-information.html?ef_id=745af40fabfc1f21c9c49ce815d23757:G:s&s_kwid=AL!3652!10!76759856878772!!!!76760083577185!!471266840!1228155570022931&cid=bid_clb_gme_r01_co_cp0000_pjt0000_bid00000_0se_bng_nt_pur_con

Dave, R., Pandey, K., Patel, R., Gour, N., & Bhatia, D. (2025). Leveraging 3D cell culture and AI technologies for next-generation drug discovery. *Cell Biomaterials*, 1(3), 100050. <https://doi.org/10.1016/j.celbio.2025.100050>

Dewani, D., Karwade, P., & Mahajan, K. S. (2023). The Invisible Struggle: The Psychosocial Aspects of Polycystic Ovary Syndrome. *Cureus*. <https://doi.org/10.7759/cureus.51321>

Dixit, P. V., & Mishra, D. K. (2025). Nanotechnology advances in treatment of reproductive diseases: From bench to bedside. *Journal of Reproductive Healthcare and Medicine*, 6, 1. https://doi.org/10.25259/JRHM_28_2024

Endometrial Organoids and Their Role in Modeling Human Infertility—PubMed. (n.d.). Retrieved October 9, 2025, from <https://pubmed.ncbi.nlm.nih.gov/40498005/>

Erten, O., & Yilmaz, B. N. (2018). Three-Dimensional Imaging in Orthodontics. *Turkish Journal of Orthodontics*, 31(3), 86–94. <https://doi.org/10.5152/TurkJOrthod.2018.17041>

Ezeh, U., Chen, Y. I., Pall, M., Buyalos, R. P., Chan, J. L., Pisarska, M. D., & Azziz, R. (2024). Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome. *Fertility and Sterility*, 121(6), 1040–1052. <https://doi.org/10.1016/j.fertnstert.2024.01.030>

Fatemi Abhari, S. M., Khanbabaei, R., Hayati Roodbari, N., Parivar, K., & Yaghmaei, P. (2020). Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone—A molecular and stereological study. *Life Sciences*, 249(March), 117515. <https://doi.org/10.1016/j.lfs.2020.117515>

Female Reproductive System Organ-On-A-Chip Model Development Services—Creative Biolabs. (n.d.). Retrieved October 9, 2025, from <https://microfluidics.creative-biolabs.com/female-reproductive-system-organ-on-a-chip-model.htm>

Friederich, J., & Lazarova-Molnar, S. (2024). Reliability assessment of manufacturing systems: A comprehensive overview, challenges and opportunities. *Journal of Manufacturing Systems*, 72, 38–58. <https://doi.org/10.1016/j.jmsy.2023.11.001>

Frontiers | Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: A systematic review. (n.d.). Retrieved October 9, 2025, from <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1106625/full>

Fukutomi, R., Ohishi, T., Koyama, Y., Pervin, M., Nakamura, Y., & Isemura, M. (2021). Beneficial Effects of Epigallocatechin-3-O-Gallate, Chlorogenic Acid, Resveratrol, and Curcumin on Neurodegenerative Diseases. *Molecules*, 26(2), 415. <https://doi.org/10.3390/molecules26020415>

Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025a). The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment. *Endocrine and Metabolic Science*, 17, 100228. <https://doi.org/10.1016/j.endmts.2025.100228>

Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025b). The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment. *Endocrine and Metabolic Science*, 17, 100228. <https://doi.org/10.1016/j.endmts.2025.100228>

Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025). Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape. *WIREs Nanomedicine and Nanobiotechnology*, 17(2), e70010. <https://doi.org/10.1002/wnan.70010>

Gorgey, A. S., Ennasr, A. N., Farkas, G. J., & Gater, D. R. (2021). Anthropometric Prediction of Visceral Adiposity in Persons With Spinal Cord Injury. *Topics in Spinal Cord Injury Rehabilitation*, 27(1), 23–35. <https://doi.org/10.46292/sci20-00055>

Grant, P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. *Phytotherapy Research*, 24(2), 186–188. <https://doi.org/10.1002/ptr.2900>

Guo, W., Xu, Y., Tian, T., Yang, S., Li, R., Qiao, J., & Zheng, X. (2023). Outcomes of the Next In Vitro Fertilization Cycle in Women with Polycystic Ovary Syndrome after a Failed In Vitro Maturation Attempt. *Journal of Clinical Medicine*, 12(17), 5761. <https://doi.org/10.3390/jcm12175761>

Gupta, U., Kosey, S., & Pal, R. (2025). Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. *Journal of Drug Delivery Science and Technology*, 111, 107181. <https://doi.org/10.1016/j.jddst.2025.107181>

Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020). Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes? *Frontiers in Cardiovascular Medicine*, 7, 570553. <https://doi.org/10.3389/fcvm.2020.570553>

Heery, Aprn, Aocns, Cbcn, M., Farley, PharmD, Bcop, S., Sparkman, PharmD, R., Healy, Bs, PharmD, J., Eighmy, PharmD, W., Zahrah, Md, G., & Zelkowitz, Md, R. (2020). Precautions for Patients Taking Aromatase Inhibitors. *Journal of the Advanced Practitioner in Oncology*, 11(2). <https://doi.org/10.6004/jadpro.2020.11.2.6>

Holland-Letz, T., & Kopp-Schneider, A. (2015). Optimal experimental designs for dose–response studies with continuous endpoints. *Archives of Toxicology*, 89(11), 2059–2068. <https://doi.org/10.1007/s00204-014-1335-2>

Höller, M., Steindl, H., Abramov-Sommariva, D., Kleemann, J., Loleit, A., Abels, C., & Stute, P. (2024). Use of Vitex agnus-castus in patients with menstrual cycle disorders: A single-center retrospective longitudinal cohort study. *Archives of Gynecology and Obstetrics*, 309(5), 2089–2098. <https://doi.org/10.1007/s00404-023-07363-4>

Human organoid systems in modeling reproductive tissue development, function, and disease | Human Reproduction | Oxford Academic. (n.d.). Retrieved October 9, 2025, from <https://academic.oup.com/humrep/article/38/8/1449/7147082?login=false>

- Intharuksa, A., Kuljarusont, S., Sasaki, Y., & Tungmunnithum, D. (2024). Flavonoids and Other Polyphenols: Bioactive Molecules from Traditional Medicine Recipes/Medicinal Plants and Their Potential for Phytopharmaceutical and Medical Application. *Molecules*, *29*(23), 5760. <https://doi.org/10.3390/molecules29235760>
- Jamshidi, N., & Cohen, M. M. (2017). The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature. *Evidence-Based Complementary and Alternative Medicine*, *2017*(1), 9217567. <https://doi.org/10.1155/2017/9217567>
- Józkowiak, M., Kobylarek, D., Bryja, A., Gogola-Mruk, J., Czajkowski, M., Skupin-Mrugalska, P., Kempisty, B., Spaczyński, R. Z., & Piotrowska-Kempisty, H. (2023). Steroidogenic activity of liposomal methylated resveratrol analog 3,4,5,4'-tetramethoxystilbene (DMU-212) in human luteinized granulosa cells in a primary three-dimensional in vitro model. *Endocrine*, *82*(3), 681–694. <https://doi.org/10.1007/s12020-023-03458-9>
- Juguilon, C., Khosravi, R., Radisic, M., & Wu, J. C. (2025). In Vitro Modeling of Interorgan Crosstalk: Multi-Organ-on-a-Chip for Studying Cardiovascular-Kidney-Metabolic Syndrome. *Circulation Research*, *136*(11), 1476–1493. <https://doi.org/10.1161/CIRCRESAHA.125.325497>
- Jyoti *, Sonia, Chennu M. M. Prasada Rao, T. R. and R. K. S. (2025). Unveiling the Anti-Diabetic Potential of Quercetin As a Natural Bioactive Compound—A Review. *International Journal of Pharmacognosy*, *12*(1), 1–23. [https://doi.org/10.13040/IJPSR.0975-8232.IJP.12\(1\).1-12](https://doi.org/10.13040/IJPSR.0975-8232.IJP.12(1).1-12)
- Kaushal, A., Musafir, A., Sharma, G., Rani, S., Singh, R. K., Kumar, A., Bhadada, S. K., Barnwal, R. P., & Singh, G. (2025). Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems. *Pharmaceutics*, *17*(6), 777. <https://doi.org/10.3390/pharmaceutics17060777>
- Kim, K.-W. (2021). Unravelling Polycystic Ovary Syndrome and Its Comorbidities. *Journal of Obesity & Metabolic Syndrome*, *30*(3), 209–221. <https://doi.org/10.7570/jomes21043>
- Kouame, K., Peter, A. I., Akang, E. N., Moodley, R., Naidu, E. C., & Azu, O. O. (2019). Histological and biochemical effects of Cinnamomum cassia nanoparticles in kidneys of diabetic Sprague-Dawley rats. *Bosnian Journal of Basic Medical Sciences*, *19*(2), 138–145. <https://doi.org/10.17305/bjbms.2019.3481>
- Kumar, A., Sundaram, K., Teng, Y., Mu, J., Sriwastva, M. K., Zhang, L., Hood, J. L., Yan, J., Zhang, X., Park, J. W., Merchant, M. L., & Zhang, H. G. (2022). Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance. *Theranostics*, *12*(3), 1388–1403. <https://doi.org/10.7150/thno.62514>
- Kumar, R. (2023). Nanotechnology in herbal medicine: Challenges and future perspectives. In *Nanotechnology in Herbal Medicine* (pp. 515–548). Elsevier. <https://doi.org/10.1016/B978-0-323-99527-6.00008-2>
- Liang, J., Gao, Y., Feng, Z., Zhang, B., Na, Z., & Li, D. (2023). Reactive oxygen species and ovarian diseases: Antioxidant strategies. *Redox Biology*, *62*, 102659. <https://doi.org/10.1016/j.redox.2023.102659>
- Lino, C., Barrias, S., Chaves, R., Adega, F., Martins-Lopes, P., & Fernandes, J. R. (2022). Biosensors as diagnostic tools in clinical applications. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1877*(3), 188726. <https://doi.org/10.1016/j.bbcan.2022.188726>
- Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J. L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., & Ma, Y. (2024). Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs. *Drug Design, Development and Therapy*, *Volume 18*, 1469–1495. <https://doi.org/10.2147/DDDT.S447496>
- Livadas, S., Anagnostis, P., Bosdou, J. K., Bantouna, D., & Papanodis, R. (2022). Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. *World Journal of Diabetes*, *13*(1), 5–26. <https://doi.org/10.4239/wjd.v13.i1.5>
- Luo, E. D., Jiang, H. M., Chen, W., Wang, Y., Tang, M., Guo, W. M., Diao, H. Y., Cai, N. Y., Yang, X., Bian, Y., & Xing, S. S. (2023). Advancements in lead therapeutic phytochemicals

polycystic ovary syndrome: A review. *Frontiers in Pharmacology*, 13(January), 1–21. <https://doi.org/10.3389/fphar.2022.1065243>

Luo, X., Jia, K., Xing, J., & Yi, J. (2024). The utilization of nanotechnology in the female reproductive system and related disorders. *Heliyon*, 10(3), e25477. <https://doi.org/10.1016/j.heliyon.2024.e25477>

Maan, P., Gautam, R., Vasudevan, S., Menon, G. R., Arora, A., Nair, A., Jabbar, P. K., & Arora, T. (2025). Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis. *Pharmaceuticals*, 18(5), 680. <https://doi.org/10.3390/ph18050680>

Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022a). Translational research: Bridging the gap between preclinical and clinical research. *Indian Journal of Pharmacology*, 54(6), 393–396. https://doi.org/10.4103/ijp.ijp_860_22

Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022b). Translational research: Bridging the gap between preclinical and clinical research. *Indian Journal of Pharmacology*, 54(6), 393–396. https://doi.org/10.4103/ijp.ijp_860_22

Malik, S., Singh, J., Goyat, R., Saharan, Y., Chaudhry, V., Umar, A., Ibrahim, A. A., Akbar, S., Ameen, S., & Baskoutas, S. (2023). Nanomaterials-based biosensor and their applications: A review. *Heliyon*, 9(9), e19929. <https://doi.org/10.1016/j.heliyon.2023.e19929>

Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025). Regulating nanomedicines: Challenges, opportunities, and the path forward. *Nanomedicine (London, England)*, 20(15), 1911–1927. <https://doi.org/10.1080/17435889.2025.2533107>

Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases. (2024). *Cardiovascular & Hematological Disorders-Drug Targets*, 24(1), 13–39. <https://doi.org/10.2174/011871529X310857240607103028>

Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023). Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development. *ACS Materials Au*, 3(6), 600–619. <https://doi.org/10.1021/acsmaterialsau.3c00032>

Meissner, H. O., Mscisz, A., Reich-Bilinska, H., Mrozikiewicz, P., Bobkiewicz-Kozłowska, T., Kedzia, B., Lowicka, A., & Barchia, I. (2006). Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (*Lepidium peruvianum* Chacon): (III) Clinical responses of early-postmenopausal women to Maca in double blind, randomized, Placebo-controlled, crossover configuration, outpatient study. *International Journal of Biomedical Science: IJBS*, 2(4), 375–394.

Merza, W. M., Yaseen, A. K., & Mahmood, M. A. (2025). FSH, LH, lipid and adipokines in Polycystic Ovary Syndrome: Clinical biochemistry insights for diagnosis and management. *The Journal of Steroid Biochemistry and Molecular Biology*, 251, 106773. <https://doi.org/10.1016/j.jsbmb.2025.106773>

Miller, L. B., Feuz, M. B., Meyer, R. G., & Meyer-Ficca, M. L. (2024). Reproductive toxicology: Keeping up with our changing world. *Frontiers in Toxicology*, 6, 1456687. <https://doi.org/10.3389/ftox.2024.1456687>

Mohammed, S., Cockburn, B. N., & Sundaram, V. (2024). Exploring the Novel Alternative and Modern Treatment Options for Polycystic Ovary Syndrome-A Review. *Integrative Medicine Reports*, 3(1), 33–42. <https://doi.org/10.1089/imr.2023.0045>

Moka, M. K., Sriram, D. K., & George, M. (2025). Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies. *Clinical Therapeutics*, 47(2), 158–167. <https://doi.org/10.1016/j.clinthera.2024.11.015>

Montanino Oliva, M., Gambioli, R., Forte, G., Porcaro, G., Aragona, C., & Unfer, V. (2022). Unopposed estrogens: Current and future perspectives. *European Review for Medical and Pharmacological Sciences*, 26(8), 2975–2989. https://doi.org/10.26355/eurrev_202204_28629

Mukherjee, S., Chopra, H., Goyal, R., Jin, S., Dong, Z., Das, T., & Bhattacharya, T. (2024). Therapeutic effect of targeted antioxidant natural products. *Discover Nano*, *19*(1), 144. <https://doi.org/10.1186/s11671-024-04100-x>

Muskan, Gupta, D., & Negi, N. P. (2022). 3D bioprinting: Printing the future and recent advances. *Bioprinting*, *27*, e00211. <https://doi.org/10.1016/j.bprint.2022.e00211>

Muthukumar, D., & Shanmugam, R. (2024a). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. <https://doi.org/10.1016/j.jddst.2024.106348>

Muthukumar, D., & Shanmugam, R. (2024b). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. <https://doi.org/10.1016/j.jddst.2024.106348>

Muthukumar, D., & Shanmugam, R. (2024c). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. <https://doi.org/10.1016/j.jddst.2024.106348>

Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential—ScienceDirect. (n.d.). Retrieved October 9, 2025, from <https://www.sciencedirect.com/science/article/abs/pii/S1773224724010177>

Nanoparticles for Polycystic Ovary Syndrome (PCOS) Therapy: Exosomes and Synthetic Nanoparticles, Challenges and Opportunities—PubMed. (n.d.). Retrieved October 9, 2025, from <https://pubmed.ncbi.nlm.nih.gov/40892199/>

Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers—PMC. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC12191273/>

Oguz, S. H., & Yildiz, B. O. (2021). An Update on Contraception in Polycystic Ovary Syndrome. *Endocrinology and Metabolism*, *36*(2), 296–311. <https://doi.org/10.3803/EnM.2021.958>

Overcoming the barriers of two-dimensional cell culture systems with three-dimensional cell culture systems: Techniques, drug discovery, and biomedical applications—ScienceDirect. (n.d.). Retrieved October 9, 2025, from <https://www.sciencedirect.com/science/article/abs/pii/B9780128239667000037>

Overview of clinical study designs—PMC. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC11009715/>

Pandey, V., Sharma, S., & Pokharel, Y. R. (2025). Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology. *Molecular Therapy Nucleic Acids*, *36*(4), 102717. <https://doi.org/10.1016/j.omtn.2025.102717>

Parashar, A. K., Hardenia, A., Dwivedi, S. K., Saraogi, G. K., & Hardenia, S. (2025). Next-Generation Nucleic Acid Delivery: A Review of Nanobiosystem Design and Applications. *Current Gene Therapy*, *25*. <https://doi.org/10.2174/0115665232367377250519114910>

Parihar, A., Parihar, D. S., Gaur, K., Arya, N., Choubey, V. K., & Khan, R. (2024). 3D bioprinting for drug development and screening: Recent trends towards personalized medicine. *Hybrid Advances*, *7*, 100320. <https://doi.org/10.1016/j.hybadv.2024.100320>

Park, C. H., Park, J. H., & Suh, Y. J. (2024). Perspective of 3D culture in medicine: Transforming disease research and therapeutic applications. *Frontiers in Bioengineering and Biotechnology*, *12*. <https://doi.org/10.3389/fbioe.2024.1491669>

Park, M., Sharma, A., Kang, C., Han, J., Malika Tripathi, K., & Lee, H. J. (2022). N-Doped Carbon Nanorods from Biomass as a Potential Antidiabetic Nanomedicine. *ACS Biomaterials Science and Engineering*, *8*(5), 2131–2141. <https://doi.org/10.1021/acsbomaterials.1c01598>

Polycystic Ovarian Syndrome: A Review of Multi-omics Analyses | Reproductive Sciences. (n.d.). Retrieved October 9, 2025, from <https://link.springer.com/article/10.1007/s43032-025-01789-8>

Prakash, S. (2023). Nano-based drug delivery system for therapeutics: A comprehensive review. *Biomedical Physics & Engineering Express*, 9(5), 052002. <https://doi.org/10.1088/2057-1976/acdb2>

Prathamesh R. Sune, Kajal S. Jumde, Pooja R. Hatwar, Ravindra L. Bakal, Samiksha D. More, & Atharv V. Korde. (2024). Nanoparticles: Classification, types and applications: A comprehensive review. *GSC Biological and Pharmaceutical Sciences*, 29(3), 190–197. <https://doi.org/10.30574/gscbps.2024.29.3.046>

Principles of nanoparticle design for overcoming biological barriers to drug delivery | *Nature Biotechnology*. (n.d.). Retrieved October 9, 2025, from <https://www.nature.com/articles/nbt.3330>

Purwar, A., & Nagpure, S. (2022). Insulin Resistance in Polycystic Ovarian Syndrome. *Cureus*. <https://doi.org/10.7759/cureus.30351>

Rabah, H. M., Mohamed, D. A., Mariah, R. A., Abd El-Khalik, S. R., Khattab, H. A., AbuHashish, N. A., Abdelsattar, A. M., Raslan, M. A., Farghal, E. E., & Eltokhy, A. K. (2023). Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole—Induced polycystic ovarian syndrome: Targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue. *Redox Report*, 28(1). <https://doi.org/10.1080/13510002.2022.2160569>

Rafiya, K., Awasthi, S., Qureshi, S. A., Hasan, N., & Ahmad, F. J. (2025). Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors. *Current Drug Delivery*. <https://doi.org/10.2174/0115672018341670241124150932>

Rai, A., Shukla, S., Gupta, R. K., & Mishra, A. (2025). ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy. *Current Pharmaceutical Design*, 31(17), 1328–1346. <https://doi.org/10.2174/0113816128329141241205063352>

Raja, M. A., Maldonado, M., Chen, J., Zhong, Y., & Gu, J. (2021). Development and evaluation of curcumin encapsulated self-assembled nanoparticles as potential remedial treatment for pcos in a female rat model. *International Journal of Nanomedicine*, 16, 6231–6247. <https://doi.org/10.2147/IJN.S302161>

Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022). Polycystic ovarian syndrome—current pharmacotherapy and clinical implications. *Taiwanese Journal of Obstetrics and Gynecology*, 61(1), 40–50. <https://doi.org/10.1016/j.tjog.2021.11.009>

Rashidi, N., Davidson, M., Apostolopoulos, V., & Nurgali, K. (2024). Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities. *Journal of Drug Delivery Science and Technology*, 95, 105599. <https://doi.org/10.1016/j.jddst.2024.105599>

Recent advances and FDA approvals in nanoformulations for drug delivery | *Journal of Nanoparticle Research*. (n.d.). Retrieved October 9, 2025, from <https://link.springer.com/article/10.1007/s11051-024-06199-6>

Recent Advances in the Management of Polycystic Ovary Syndrome: A Review Article—PMC. (n.d.). Retrieved September 27, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC9440853/>

Recent Review on Biological Barriers and Host–Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies—PMC. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC11360117/>

Rodríguez-Yoldi, M. J. (2021). Anti-Inflammatory and Antioxidant Properties of Plant Extracts. *Antioxidants*, 10(6), 921. <https://doi.org/10.3390/antiox10060921>

Ryu, Y., Kim, S. W., Kim, Y. Y., & Ku, S.-Y. (2019). Animal Models for Human Polycystic Ovary Syndrome (PCOS) Focused on the Use of Indirect Hormonal Perturbations: A Review of the Literature. *International Journal of Molecular Sciences*, 20(11), 2720. <https://doi.org/10.3390/ijms20112720>

Sabbadin, C., Andrisani, A., Zermiani, M., Donà, G., Bordin, L., Ragazzi, E., Boscaro, M., Ambrosini, G., & Armanini, D. (2016). Spironolactone and intermenstrual bleeding in

polycystic ovary syndrome with normal BMI. *Journal of Endocrinological Investigation*, 39(9), 1015–1021. <https://doi.org/10.1007/s40618-016-0466-0>

Sabir, S., Thani, A. S. B., & Abbas, Q. (2025). Nanotechnology in cancer treatment: Revolutionizing strategies against drug resistance. *Frontiers in Bioengineering and Biotechnology*, 13, 1548588. <https://doi.org/10.3389/fbioe.2025.1548588>

Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. *Journal of Drug Delivery Science and Technology*, 63, 102487. <https://doi.org/10.1016/j.jddst.2021.102487>

Salm, S., Rutz, J., Van Den Akker, M., Blaheta, R. A., & Bachmeier, B. E. (2023). Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments. *Frontiers in Pharmacology*, 14, 1234701. <https://doi.org/10.3389/fphar.2023.1234701>

Sarkar, K., Chatterjee, A., Bankura, B., Bank, S., Paul, N., Chatterjee, S., Das, A., Dutta, K., Chakraborty, S., De, S., Al-Masud, A. A., Khan, G. A., Chattopadhyay, D., & Das, M. (2024). Efficacy of pegylated Graphene oxide quantum dots as a nanoconjugate sustained release metformin delivery system in in vitro insulin resistance model. *PLoS ONE*, 19(8 August), 1–15. <https://doi.org/10.1371/journal.pone.0307166>

Serrano, D. R., Kara, A., Yuste, I., Luciano, F. C., Ongoren, B., Anaya, B. J., Molina, G., Diez, L., Ramirez, B. I., Ramirez, I. O., Sánchez-Guirales, S. A., Fernández-García, R., Bautista, L., Ruiz, H. K., & Lalatsa, A. (2023). 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. *Pharmaceutics*, 15(2), 313. <https://doi.org/10.3390/pharmaceutics15020313>

Shandilya, R., Pathak, N., Lohiya, N. K., Sharma, R. S., & Mishra, P. K. (2020). Nanotechnology in reproductive medicine: Opportunities for clinical translation. *Clinical and Experimental Reproductive Medicine*, 47(4), 245–262. <https://doi.org/10.5653/cerm.2020.03650>

Shang, C., Lin, H., Fang, X., Wang, Y., Jiang, Z., Qu, Y., Xiang, M., Shen, Z., Xin, L., Lu, Y., Gao, J., & Cui, X. (2021). Beneficial effects of cinnamon and its extracts in the management of cardiovascular diseases and diabetes. *Food & Function*, 12(24), 12194–12220. <https://doi.org/10.1039/D1FO01935J>

Sheikh, I. M., Hassan, O. A., Adam, S. M., Ali, A. I., Ogedegbe, O. J., Tabowei, G., Barbarawi, A., Yussuf, F. M., & Nor, M. A. (2023). Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review. *Cureus*. <https://doi.org/10.7759/cureus.46911>

Shi, M., Li, X., Xing, L., Li, Z., Zhou, S., Wang, Z., Zou, X., She, Y., Zhao, R., & Qin, D. (2024). Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease. *Pharmaceutics*, 16(12), 1556. <https://doi.org/10.3390/pharmaceutics16121556>

Singh, D. (2025). Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). *Current Analytical Chemistry*, 21(4), 263–275. <https://doi.org/10.2174/0115734110311450240612051821>

Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. *Next Research*, 1(1), 100004. <https://doi.org/10.1016/j.nexres.2024.100004>

Su, P., Chen, C., & Sun, Y. (2025). Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. *Journal of Ovarian Research*, 18(1), 34. <https://doi.org/10.1186/s13048-025-01621-6>

Teja, P. K., Mithiya, J., Kate, A. S., Bairwa, K., & Chauthe, S. K. (2022). Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview. *Phytomedicine*, 96, 153890. <https://doi.org/10.1016/j.phymed.2021.153890>

The interaction between nanoparticles and immune system: Application in the treatment of inflammatory diseases | *Journal of Nanobiotechnology* | Full Text. (n.d.). Retrieved October 9, 2025, from <https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-022-01343-7>

The Promise of Nanotechnology in Personalized Medicine—PMC. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC9142986/>

Therapeutic Nanoparticles and Their Targeted Delivery Applications—PMC. (n.d.). Retrieved October 9, 2025, from <https://pmc.ncbi.nlm.nih.gov/articles/PMC7248934/>

Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects. (n.d.). Retrieved October 9, 2025, from <https://www.mdpi.com/2072-6694/17/19/3239>

Unluhizarci, K., Karaca, Z., & Kelestimur, F. (2021). Role of insulin and insulin resistance in androgen excess disorders. *World Journal of Diabetes*, *12*(5), 616–629. <https://doi.org/10.4239/wjd.v12.i5.616>

Vasudevan, S., Gautam, R., Maan, P., Arora, A., Ganie, A., Jabbar, P. K., & Arora, T. (2025). A sustainable public health framework for PCOS management in low- and middle-income countries: A narrative review. *Frontiers in Reproductive Health*, *7*. <https://doi.org/10.3389/frph.2025.1627670>

Veerasingam, R. (2024). Development of Nanoparticles: Recent Developments and Future Prospects. In S. Bose, A. C. Shukla, M. R. Baig, & S. Banerjee (Eds.), *Concepts in Pharmaceutical Biotechnology and Drug Development* (pp. 67–89). Springer Nature Singapore. https://doi.org/10.1007/978-981-97-1148-2_5

Wang, H., & Yang, L. (2025). Ovarian Mechanobiology: Understanding the Interplay Between Mechanics and Follicular Development. *Cells*, *14*(5), 355. <https://doi.org/10.3390/cells14050355>

Wang, K., Li, Y., & Chen, Y. (2023). Androgen excess: A hallmark of polycystic ovary syndrome. *Frontiers in Endocrinology*, *14*, 1273542. <https://doi.org/10.3389/fendo.2023.1273542>

Yang, C., & Merlin, D. (2023). Challenges to Safe Nanomedicine Treatment. *Nanomaterials*, *13*(7), 1171. <https://doi.org/10.3390/nano13071171>

Yilmaz, S., Yilmaz Sezer, N., Gönenç, İ. M., İlhan, S. E., & Yilmaz, E. (2018). Safety of clomiphene citrate: A literature review. *Cytotechnology*, *70*(2), 489–495. <https://doi.org/10.1007/s10616-017-0169-1>

Yoon, J. H., Ahn, S.-Y., Jung, S.-H., Lee, J.-J., Choi, W., Park, J. Y., Hong, A. R., Kim, H. K., & Kang, H.-C. (2021). Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study. *BioMed Research International*, *2021*(1), 2330417. <https://doi.org/10.1155/2021/2330417>

Zhao, H., Wang, D., Xing, C., Lv, B., Wang, X., & He, B. (2023). Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4 α . *The Journal of Steroid Biochemistry and Molecular Biology*, *229*, 106265. <https://doi.org/10.1016/j.jsbmb.2023.106265>

Zhao, S., Tang, Y., Wang, R., & Najafi, M. (2022). Mechanisms of cancer cell death induction by paclitaxel: An updated review. *Apoptosis*, *27*(9–10), 647–667. <https://doi.org/10.1007/s10495-022-01750-z>